CPA
THRD

Capital Performance Advisors’s Third Harmonic Bio THRD Stock Holding History

Capital Performance Advisors’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25
Closed -$339 – 2439
2024
Q3 		$339 Buy
+25
New +$310 ﹤0.01% 2420

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Performance Advisors's THRD Position: Q4 2024 in Review

Capital Performance Advisors sold out of Third Harmonic Bio (THRD) in Q4 2024, closing a stake of 25 shares — an estimated $339 sold.

Capital Performance Advisors first reported a position in THRD in Q3 2024 and held it in 1 quarter. The position peaked at $339 in Q3 2024. 96 funds tracked by Wall St. Rank hold THRD as of Q4 2024.

  • Capital Performance Advisors reported no remaining Third Harmonic Bio position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 25 Third Harmonic Bio shares in Q4 2024, an estimated $339.
  • Capital Performance Advisors first reported a position in Third Harmonic Bio in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Third Harmonic Bio position peaked at $339 in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.